Ophthalmic uses of PPARgamma agonists and PPARgamma antagonists
US6316465A · kind A · utility
17Cited by
3References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 28, 1999 |
| Grant date | Nov 13, 2001 |
| Priority date | — |
| Expiry date | Jun 28, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/557
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating diseases of ocular tissues expressing the nuclear receptor PPAR.gamma., by inhibiting the inflammatory response, the neovascularization and angiogenesis, and programmed cell death (apoptosis) in these target tissues, comprising administering to a human or animal in need of treatment an effective amount of a compound that modifies the activity of PPAR.gamma., or pharmaceutically acceptable salts and solvates thereof. Novel compounds and methods for their synthesis are provided, including a compound having the general structure: ##STR1##
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.